Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

Journal of Neurology

Volumn 260, Issue 8, 2013, Pages 2023-2032

  Cohen, Jeffrey A ^a   Barkhof, Frederik ^b   Comi, Giancarlo ^c   Izquierdo, Guillermo ^d   Khatri, Bhupendra ^e   Montalban, Xavier ^f   Pelletier, Jean ^g   Eckert, Benjamin ^h   Häring, Dieter A ^h   Francis, Gordon ^h  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e ST LUKE S MEDICAL CENTER   (United States)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g TIMONE HOSPITAL   (France)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fingolimod; Interferon beta; MRI; Multiple sclerosis; Randomized clinical trial; Subgroup analysis

Indexed keywords

BETA INTERFERON; BETA INTERFERON 1A; FINGOLIMOD; GADOLINIUM; UNCLASSIFIED DRUG;

ADULT; ANNUALIZED RELAPSE RATE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84881550415     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6932-0     Document Type: Article

References (17)

1. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
2. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
3. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10(6):520-529
4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346(3):158-164
5. Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129(Pt 3):595-605
6. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt 4):770-782
7. Losseff NA, Miller DH, Kidd D, Thompson AJ (2001) The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis - preliminary results. Mult Scler 7(1):23-25
8. Scott TF, Schramke CJ, Novero J, Chieffe C (2000) Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 55(5):689-693
9. Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Haring DA, Francis G, Kappos L (2012) Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 11(5):420-428
10. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1(1):43-46
11. Tremlett H, Zhao Y, Joseph J, Devonshire V (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79(12):1368-1374
12. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP (2008) Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 59(3-4):131-135
13. Zwibel HL (2006) Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 113(6):378-386
14. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898-904
15. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285-294
16. Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 46(2):197-206
17. PRISMS study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Lancet 352(9139):1498-1504